
Sun Pharma: Network and Portfolio Review
Optimise, not shrink, the US generics network, and wait for the tariff text before building in the US
The US decline is lenalidomide, not the base.
- +$122M
- optimise against defending every site, under the 200% plan
Product & StrategyReport
PDF









